Background: Several reports suggest that higher levels of serum uric acid are associated with a lower risk of Parkinson disease (PD). None of these studies, however, evaluated the potential association between gout, a condition characterized by hyperuricemia, and the risk of PD.
and the risk of developing PD in the General Practice Research Database (GPRD), a large population-based database in the UK.
METHODS Study population. The GPRD includes over 3 million Britons whose physicians have been trained to record their patients' information in a standard manner and have agreed to supply it anonymously for research purposes. Information recorded in the GPRD includes prescriptions, which are computer generated by the physicians and automatically transcribed into the computer record, medical diagnoses, and hospital admissions. The GPRD has been shown to be of satisfactory quality for research purposes. 10, 11 A detailed description of our study population has been published elsewhere. 12, 13 Briefly, we defined a cohort of GPRD participants with no history of PD or parkinsonismrelated drug use at baseline. Each individual's follow-up started on January 1, 1995, or after 3 years of continuous recorded medical history, whichever came later, and ended at the first computerized PD symptom (tremor, rigidity, bradykinesia, abnormal gait), PD diagnosis, use of drugs that may cause parkinsonism, last data collection, death, or December 31, 2001, whichever came first. The cohort comprised more than 2 million individuals and more than 8 million person-years. PD ascertainment. There were 1,904 individuals with a computerized diagnosis of PD in the study cohort. To evaluate the validity of the computer-recorded PD diagnosis, we requested photocopies of all PD-related paper records from a random sample of 7% of patients. The diagnostic procedure has been described extensively elsewhere. 12 In brief, we identified parkinsonism as the presence of lateralized isolated resting tremor, two cardinal signs, or a cardinal sign plus antiparkinsonian treatment. We classified parkinsonism as drug-induced, vascular, other secondary parkinsonism, Parkinson-plus syndrome, parkinsonism dementia, unspecified parkinsonism, and PD (parkinsonism that did not fit in the above categories and that did not show any important signs of involvement of other CNS regions in the first year). Review of medical records confirmed the computerized diagnosis in 81% of patients for whom medical records were available. This figure was 90% for those who had received two or more prescriptions for the treatment of PD during the follow-up. Therefore, for the purpose of this study, we considered as cases 1,258 individuals with a computerized diagnosis of PD and at least two prescriptions to treat parkinsonian signs.
Study design. The date of PD onset (index date) of the 1,258 cases was defined as the minimum of the date of first diagnosis of PD, date of first prescription of a PD-related drug, and date of first report of PD symptoms. Because PD has a preclinical phase, we advanced the index date 2 years to avoid the effect of unrecognized disease in the exposures of interest. Up to 10 controls per case were randomly selected, matched by age, sex, practice, and year of enrolment in the GPRD. Controls had the same index date as their matched case. From the 1,258 cases, 1,052 had at least one eligible control and, therefore, were included in the analysis.
Exposure assessment. We identified diagnoses of gout in the computerized records occurring before the index date. If the diagnosis was recorded several times, we used the earliest annotation to define date of diagnosis. A previous study showed a validity of 90% for gout diagnoses recorded in the GPRD when they were associated with use of anti-gout medication. 14 Additionally, an analysis of the incidence of gout in the GPRD provided figures similar to other populationbased studies, suggesting that most cases of gout are correctly recorded. 15 Drug prescriptions are computer generated by the physicians and automatically transcribed into the computer record. We identified all prescriptions of allopurinol, probenecid, colchicine, and sulfinpyrazone. Allopurinol accounted for more than 90% of these prescriptions. Length of medication use was computed adding periods of prescriptions with 3 or less months between them.
Finally, we defined treated gout as the presence of a gout diagnosis plus at least one anti-gout prescription before the index date, and non-treated gout if no prescriptions were associated with the gout diagnosis.
Statistical analysis.
To estimate the risk of PD associated with a prior diagnosis of gout, we used a conditional logistic regression model to compute ORs of PD and their 95% CIs by gout history, adjusted for the matching factors. Smoking status (current smoker, past smoker, never smoker, missing status) was added as a covariate to the model. Under our design, the OR is an unbiased estimator of the incidence rate ratio.
As a secondary analysis, we estimated the intent-to-treat PD incidence ratio for initiation of anti-gout medication. To do so, we conceptualized our analysis as a case-control study nested in a nonrandomized trial 16 of individuals who did not have PD or use parkinsonism-related drugs, had at least 1 year of continuous data recording, and had not used antigout medication for at least 6 months at baseline (January 1993 because the index date was advanced 2 years). Cases and controls who met these criteria were included in a logistic model that included initiation of anti-gout treatment, recent use of anti-gout medication (6 months to 1 year), past use of anti-gout medication (more than 1 year), smoking (ever smoker, never smoker, missing) at baseline. The OR for initiation of anti-gout medication estimates the intention-to-treat incidence ratio. We repeated the process for each month until July 1999 (2 years before the last case of PD) and pooled the results in a single logistic model with calendar month (linear and quadratic) as an additional covariate.
RESULTS
The study included 1,052 PD cases and 6,634 controls. Their characteristics are shown in table 1. A previous diagnosis of gout was associated with a lower risk of developing PD in the future (OR 0.69, 95% CI 0.48, 0.99). Compared with individuals without history of gout, the OR (95% CI) of PD among those with a gout diagnosis and on anti-gout medication was 0.61 (0.34, 1.07), while among those not treated was 0.75 (0.47, 1.19).
As shown in table 2, a gout diagnosis or antigout treatment were associated with a lower risk of PD among men, nonsmokers, and older (Ն60) individuals, but not among women, smokers, and individuals younger than 60. None of these inter-actions, however, achieved the traditional level of significance. When we repeated the overall analysis after advancing the index date 4 years instead of 2 years, the OR (95% CI) of PD was 0.63 (0.41, 0.96) for a previous diagnosis of gout and 0.46 (0.24, 0.89) for history of gout and at least one anti-gout prescription.
From our study population, 1,014 cases and 6,258 controls were eligible for at least one of the nonrandomized trials. Each individual participated in an average of 25 trials (range 1 to 77). The median time on treatment was 9 months (range 0 to 56). Initiating treatment with an antigout drug was associated with lower risk of PD (OR 0.57, 95% CI 0.19, 1.70), although the 95% CIs are wide. The number of individuals exposed to a medication other than allopurinol was too low to draw conclusions about the association between different drugs and PD risk. DISCUSSION We found a 30% reduction in the incidence of PD among individuals with a history of gout. This reduction in the risk of PD was only evident among men, nonsmokers, and those aged 60 or older. We also found a lower risk of PD among individuals who started using anti-gout medication, a marker for high levels of serum uric acid or severe gout, though the CIs were too wide to draw meaningful conclusions.
Our findings are unlikely to be the result of differential misclassification of the exposure (because diagnosis of gout and drug prescriptions were recorded before the onset of PD) or bias due to inappropriate selection of controls (because the case-control study was nested in a well defined cohort). Although in our analysis we adjusted for matching factors (age, sex, practice) and smoking, an unmeasured factor strongly related both to gout and PD risk might theoretically explain our results. For example, our analysis did not adjust for coffee consumption, a factor associated with a lower PD risk (at least among men 17 ) and that has been suggested to reduce serum uric acid levels. 18 However, the potential confounding from coffee would bias our estimates toward a higher risk of PD among individuals with gout, Table 1 Characteristics of cases and controls Numbers refer to percentage unless otherwise stated. PD ϭ Parkinson disease. which cannot explain their observed lower PD risk.
A previous case-control study including 79 prevalent cases of PD and 107 controls reported lower levels of serum uric acid among patients with PD. 8 Three prospective studies have assessed the association between serum uric acid and the subsequent risk of PD. In the Honolulu Heart Study, which followed about 8,000 Japanese-American men living in Hawaii, individuals with serum uric acid at baseline over the median value had a 40% reduction in PD risk. 5 More recently, a report from the Rotterdam Study showed that an increase of one SD in serum uric acid was associated with a 30% reduction in PD risk. 6 Finally, in the Health Professionals Follow-up Study, men in the higher quartile of serum uric acid had a 55% lower risk of PD compared with those with the lowest levels of uric acid. 7 These studies were conducted only among men or their small sample size made it unfeasible to assess the association by sex, age, or other characteristics. In addition to these studies focusing on the risk of developing PD, the role of serum uric acid as a predictor of PD progression has been assessed in the PRECEPT and the DATATOP trials. 19, 20 In both studies, high levels of serum uric acid were associated with a better neurologic outcome in men, but not women, with PD. High levels of uric acid in CSF were also associated with a better outcome in the DATATOP trial. 20 Though these two studies are being conducted in patients who already developed PD, their results are consistent with those from the previous epidemiologic studies.
Different biologic mechanisms can account for the association between gout, hyperuricemia, and lower PD risk. Uric acid has shown beneficial effects in animal models of neurologic disorders, including multiple sclerosis and spinal cord injury. 21, 22 The observed protection seems to be mediated through inhibition of peroxynitritemediated neurotoxicity, a mechanism also involved in PD pathogenesis. 23 Similarly, uric acid has been shown to reduce oxidative damage by free radicals in DNA molecules. 24 Gout in women was not associated with a lower PD risk in our study. This is consistent with results from the PRECEPT and DATATOP trials. 19, 20 Sex-specific associations have been reported between PD and factors such as nonsteroidal anti-inflammatory drugs, 13 caffeine, 25 or serum cholesterol levels. 26 Because the risk of developing gout among hyperuricemic women is lower than among hyperuricemic men, 27 the higher proportion of hyper-uricemic women without a gout diagnosis might dilute any potential effect of uric acid on PD risk.
Similarly, gout in smokers was not associated with a lower PD risk, which might be explained by a smoking-related reduction in the antioxidant pool that counteracts the potential beneficial effect of hyperuricemia, 28 or to decreased levels of serum uric acid 29 and a lower risk of developing hyperuricemia among smokers 30 compared with nonsmokers. Consistent with our results, the Honolulu Heart Study reported a higher reduction in PD risk associated with high serum uric acid among nonsmokers than among smokers. 5 Also, gout was not associated with a lower PD risk in young individuals, which could be explained by the need of a long latent period to observe the beneficial effect of hyperuricemia on PD risk.
Our study complements previous reports on the association between serum uric acid and risk of PD in two ways. First, we assessed the potential protective role of serum uric acid using a different approach. Our results were consistent with those from previous studies. Second, the large number of PD cases allowed us to study the association of history of gout and PD risk among different subgroups. Questions regarding the potential effect modification by age, sex, or smoking status remain to be solved.
